Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors
暂无分享,去创建一个
P. Elson | E. Hsi | B. Pohlman | R. Steinle | B. Richendollar | T. Jin | R. Tsao
[1] L. Szekely,et al. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] M. Hattori,et al. Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients. , 2008, Clinical nephrology.
[3] A. Cerwenka,et al. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.
[4] T. Kelley,et al. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. , 2007, American journal of clinical pathology.
[5] G. Salles,et al. Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?. , 2007 .
[6] E. Hsi,et al. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. , 2007, Archives of pathology & laboratory medicine.
[7] K. Faber,et al. Effects of different immunosuppressive regimens on regulatory T‐cells in noninflamed colon of liver transplant recipients , 2007, Inflammatory bowel diseases.
[8] B. Dörken,et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.
[9] H. Nilsson‐Ehle,et al. The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma , 2007, British journal of haematology.
[10] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Horning,et al. Mature Results of a Prospective Trial of Rituximab in Patients (Pt) with Post Transplant Lymphoproliferative Disorder (PTLD) Unresponsive or Ineligible for Reduced Immunosuppression (RIS). , 2006 .
[12] Emili Montserrat,et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.
[13] B. Moulin,et al. Post‐Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] Irene Ghobrial,et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. , 2006, Blood.
[15] Xin Wei Wang,et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.
[16] G. Grabenbauer,et al. Tumor-Infiltrating Cytotoxic T Cells but not Regulatory T Cells Predict Outcome in Anal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.
[17] E. Shevach,et al. Activated CD4+CD25+ T cells selectively kill B lymphocytes. , 2006, Blood.
[18] T. Habermann,et al. Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] G. Salles,et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.
[20] K. Olthoff,et al. Treatment of PTLD with Rituximab or Chemotherapy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] C. Canter,et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study , 2006, The Lancet.
[22] R. Kandaswamy,et al. Posttransplant Lymphoproliferative Disorder in Pancreas Transplantation: A Single-Center Experience , 2005, Transplantation.
[23] R. Alloway,et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. , 2005, Transplantation proceedings.
[24] Giovanna Roncador,et al. Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.
[25] T. Habermann,et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era , 2005, Leukemia & lymphoma.
[26] E. Haddad,et al. RELATIONSHIP BETWEEN CD8+ T-CELL PHENOTYPE AND FUNCTION, EPSTEIN-BARR VIRUS LOAD, AND CLINICAL OUTCOME IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY1 , 2004, Transplantation.
[27] G. Opelz,et al. Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[28] M. Steele,et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. , 2003, Chest.
[29] S. Hamilton-Dutoit,et al. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? , 2003, Transplantation.
[30] R. Hornung,et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment , 2003, Transplantation.
[31] G. Mazariegos,et al. Posttransplant Lymphoproliferative Disorders in Liver Transplantation: A 20-Year Experience , 2002, Annals of surgery.
[32] E. Yakirevich,et al. Activated status of tumour‐infiltrating lymphocytes and apoptosis in testicular seminoma , 2002, The Journal of pathology.
[33] D. Wigle,et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. , 2001, Transplantation.
[34] S. Cockfield. Identifying the patient at risk for post‐transplant lymphoproliferative disorder , 2001, Transplant infectious disease : an official journal of the Transplantation Society.
[35] R. Porcher,et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] T. Tsurumi,et al. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. , 2000, The Journal of infectious diseases.
[37] M. DeBaun,et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. , 2000, American journal of respiratory and critical care medicine.
[38] M. Yacoub,et al. Risk of lymphoid neoplasia after cardiothoracic transplantation. a cohort study of the relation to Epstein-Barr virus. , 2000, Transplantation.
[39] S. Swerdlow,et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? , 2000, The American journal of surgical pathology.
[40] T. Whiteside,et al. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. , 1999, Leukemia & lymphoma.
[41] G. Rennert,et al. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[42] E. Jaffe,et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.
[43] P. Gaulard,et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation , 1999, Hepatology.
[44] T. Starzl,et al. Cytokine mRNA profiles in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders , 1999, Clinical transplantation.
[45] J. Thistlethwaite,et al. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. , 1997, The Journal of pediatrics.
[46] M. Yacoub,et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. , 1996, The Journal of general virology.
[47] F. Davi,et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] R. Fisher,et al. Aggressive treatment for postcardiac transplant lymphoproliferation. , 1995, Blood.
[49] W. Weimar,et al. Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load , 1992, Transplant international : official journal of the European Society for Organ Transplantation.
[50] V. Godfrey,et al. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. , 1991, The American journal of pathology.
[51] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.
[52] T. Beveridge,et al. LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN THERAPY , 1984, The Lancet.
[53] T. Starzl,et al. REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.
[54] D. Titterington,et al. INFLUENCE OF HLA MATCHING AND BLOOD TRANSFUSION ON RENAL ALLOGRAFT SURVIVAL , 1978, Transplantation.
[55] J. H. Harrison,et al. Five Years' Experience in Renal Transplantation with Immunosuppressive Drugs: Survival, Function, Complications, and the Role of Lymphocyte Depletion by Thoracic Duct Fistula , 1968, Annals of surgery.
[56] T. Starzl,et al. Orthotopic homotransplantation of the human liver. , 1968 .
[57] V. Levitsky,et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. , 2006, Haematologica.
[58] B. Sander,et al. Posttransplant lymphoma—A single-center experience of 500 liver transplantations , 2004, Medical oncology.
[59] T. Habermann,et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.